(171 days)
Not Found
No
The device description and performance studies focus on the mechanical properties and clinical outcomes of a physical stent and its delivery system, with no mention of AI/ML components or functions.
Yes
The device is used for palliative treatment of colonic obstruction or strictures and to relieve large bowel obstruction prior to colectomy, which are therapeutic interventions.
No
The device is described as a flexible, self-expanding stent used for palliative treatment of colonic obstruction or strictures and to relieve large bowel obstruction prior to colectomy. These are therapeutic uses, not diagnostic ones.
No
The device description clearly outlines a physical, implantable stent made of nitinol wire, along with a delivery system including catheters and a handle. This is a hardware medical device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes a device used for the treatment of colonic obstruction and strictures caused by malignant neoplasms. This is a therapeutic intervention, not a diagnostic one.
- Device Description: The device is a physical stent designed to be implanted within the colon to open up blockages. This is a medical device used for treatment, not for analyzing samples from the body to diagnose a condition.
- Performance Studies: The performance study focuses on clinical outcomes related to the treatment of the condition (symptom relief, technical success of implantation, adverse events related to the device's function within the body). It does not involve the analysis of biological samples for diagnostic purposes.
IVD devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for the diagnosis, monitoring, or treatment of a disease or condition. This device does not perform such a function.
N/A
Intended Use / Indications for Use
This device is used for palliative treatment of colonic obstruction or colonic strictures caused by malignant neoplasms, and to relieve large bowel obstruction prior to colectomy in patients with malignant strictures.
Product codes (comma separated list FDA assigned to the subject device)
MQR
Device Description
Stent Description: This flexible, self-expanding stent is constructed of nitinol wire. The total length of the stent is indicated by radiopaque markers on the inner catheter, indicating the actual length of the stent at nominal stent diameter. The stent has flanges at both stent ends. The stent is provided with a body diameter of 25mm and flange diameters of 30mm and is provided in three lengths 6cm, 8cm and 10cm.
Introducer System Description: The stent is mounted on an inner catheter, which accepts a 0.035 inch wire guide and is constrained by an outer catheter. A pistol-grip delivery handle allows stent deployment or recapture. The introducer system diameter is 10 Fr and working length is 230cm.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Allows placement using fluoroscopic techniques
Anatomical Site
Colonic
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance Testing-Bench: The bench testing was conducted in accordance with various applicable ASTM standards and in accordance with FDA's Guidance for the Content of Premarket Notifications for Esophageal and Tracheal Prostheses. In the absence of specific colonic stent guidance this guidance was considered relevant to colonic stents. The following bench tests were carried out: deployment testing, expansion force testing, compression force testing, dimensional testing, corrosion testing, tensile strength testing and MRI testing. The bench testing was successfully completed. Results of the testing provide reasonable assurance that the Evolution® Colonic Stent System will function as intended.
Biocompatibility: Biocompatibility testing in compliance with ISO 10993-1 and FDA's Guidance for the Content of Premarket Notifications for Esophageal and Tracheal Prostheses supports the safety of the Evolution® Colonic Stent System.
Performance Testing-Clinical: A 80 patient registry study was conducted to compile clinical data on use of the Evolution® Colonic Stent System for palliation of symptoms due to colonic obstruction or stricture caused by malignant neoplasms, and as a "bridge to surgery" to relieve large bowel obstruction prior to potential colectomy in patients with malignant strictures. Data on clinical success, technical success, acute procedural success, implant duration, symptoms at follow-up, and adverse events were collected. Follow-up occurred to 6 months or death. The data demonstrate acceptable technical success, clinical success, acute procedural success were achieved, and symptom relief. Adverse events included perforation, migration, and obstruction. Importantly, no adverse events were associated with device malfunction and no deaths were considered to be caused by a device complication.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.3610 Esophageal prosthesis.
(a)
Identification. An esophageal prosthesis is a rigid, flexible, or expandable tubular device made of a plastic, metal, or polymeric material that is intended to be implanted to restore the structure and/or function of the esophagus. The metal esophageal prosthesis may be uncovered or covered with a polymeric material. This device may also include a device delivery system.(b)
Classification. Class II. The special control for this device is FDA's “Guidance for the Content of Premarket Notification Submissions for Esophageal and Tracheal Prostheses.”
0
MAY 17 2012
.
K113510; Cook Ireland Evolution® Colonic Stent System
・
・
.
·
| Section 5.0 510(k) Summary | |
|---|---|
| Name: | Cook Ireland Ltd |
| Address: | O 'Halloran Road |
| National Technology Park | |
| Limerick, Ireland | |
| Phone: | 353 61 334440 |
| Fax: | 353 61 239293 |
| Contact Persons: | Jacinta Kilmartin, Regulatory Affairs Specialist |
| Emmett Devereux, Director Quality & Regulatory Affairs | |
| Phone: | 353 61 334440 |
| Fax: | 353 61 239 293 |
| Date: | April 25, 2012 |
| Trade Name: | Evolution® Colonic Stent System |
| Common Name: | Stent, colonic, metallic, expandable |
| Classification Name: | Stent, colonic, metallic, expandable |
| (21 CFR 878.3610, Product Code: MQR) | |
| Predicate Devices: | Boston Scientific Wallstent® Enteral Endoprosthesis with |
| Unistep™ Plus Delivery System (K000281) | |
| Boston Scientific WallFlex™ Enteral Colonic Stent with | |
| Anchor Lock Delivery System (K061877) | |
| Cook Evolution® Duodenal Stent System (K101530) |
Page 1 of 4
:
3 1 of 4
1
K113510
pg2064
Description of the Device:
Stent Description:
This flexible, self-expanding stent is constructed of nitinol wire. The total length of the stent is indicated by radiopaque markers on the inner catheter, indicating the actual length of the stent at nominal stent diameter. The stent has flanges at both stent ends. The stent is provided with a body diameter of 25mm and flange diameters of 30mm and is provided in three lengths 6cm, 8cm and 10cm.
Introducer System Description:
The stent is mounted on an inner catheter, which accepts a 0.035 inch wire guide and is constrained by an outer catheter. A pistol-grip delivery handle allows stent deployment or recapture. The introducer system diameter is 10 Fr and working length is 230cm.
This device is used for palliative treatment of colonic obstruction or colonic strictures caused by malignant neoplasms, and to relieve large bowel obstruction prior to colectomy in patients with malignant strictures. The Evolution® Colonic Stent System is substantially equivalent to the currently marketed predicate devices, the Boston Scientific Wallstent® Enteral Endoprosthesis with Unistep™ Plus Delivery System (K000281), the Boston Scientific WallFlex™ Enteral Colonic Stent with Anchor Lock Delivery System (K061877) and the Cook Evolution® Duodenal Stent System (K101530). The proposed device shares many technological characteristics with at least one of the predicate devices (or fall within the range of the predicates) in terms of the following:
- . Stents:
Dimensions (Diameter & Length), ୍
Materials (i.e. nitinol), o
O Self Expanding Stent,
Indications for use:
Comparison of Characteristics:
2
K113510
pg 3 of 4
- o Braided Stent Construction,
- o Number of Expanded Ends.
- Introduction System:
- Materials of construction, o
- Working length dimensions, o
- o Allows stent deployment and recapture.
- o Supplied with a preloaded stent,
- o Allows placement using fluoroscopic techniques,
- Compatibility with an endoscope o
- Intended use .
- All are intended for single use, are supplied sterile and . are not intended to be removed.
Performance (bench and clinical) testing was carried out to determine the equivalence of the Evolution® Colonic Stent System to predicate devices and to verify the safety and effectiveness of the device.
Performance Testing-Bench:
The bench testing was conducted in accordance with various applicable ASTM standards and in accordance with FDA's Guidance for the Content of Premarket Notifications for Esophageal and Tracheal Prostheses. In the absence of specific colonic stent guidance this guidance was considered relevant to colonic stents. The following bench tests were carried out: deployment testing, expansion force testing, compression force testing, dimensional testing, corrosion testing, tensile strength testing and MRI testing. The bench testing was successfully completed. Results of the testing provide reasonable assurance that the Evolution® Colonic Stent System will function as intended.
Biocompatibility:
Biocompatibility testing in compliance with ISO 10993-1 and FDA's Guidance for the Content of Premarket Notifications for Esophageal and Tracheal Prostheses supports the safety of the Evolution® Colonic Stent
Performance Data:
3
K113510
pg 4 of 4
System.
Performance Testing-Clinical:
A 80 patient registry study was conducted to compile clinical data on use of the Evolution® Colonic Stent System for palliation of symptoms due to colonic obstruction or stricture caused by malignant neoplasms, and as a "bridge to surgery" to relieve large bowel obstruction prior to potential colectomy in patients with malignant strictures. Data on clinical success, technical success, acute procedural success, implant duration, symptoms at follow-up, and adverse events were collected. Follow-up occurred to 6 months or death. The data demonstrate acceptable technical success, clinical success, acute procedural success were achieved, and symptom relief. Adverse events included perforation, migration, and obstruction. Importantly, no adverse events were associated with device malfunction and no deaths were considered to be caused by a device complication.
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the logo is an abstract symbol that resembles an eagle or other bird.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -- WO66-G609 Silver Spring, MD 20993-0002
Ms. Jacinta Kilmartin Regulatory Affairs Speacialist Cook Ireland Ltd. O' Halloran Road, National Technology Park LIMERICK IRELAND
MAY 1 7 2012
Re: K113510
Trade/Device Name: Evolution® Colonic Stent System Regulation Number: 21 CFR& 878.3610 Regulation Name: Esophageal prosthesis Regulatory Class: II Product Code: MQR Dated: April 25, 2012 Received: April 30, 2012
Dear Ms. Kilmartin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
5
Page 2 -
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
http://www.fda.gov/MedicalDevices/ResourcestoYou/Industry/default.htm.
Sincerely yours,
Benjamin R. Eick
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Section 4.0 Indications for Use
5510
510(k) Number (if known): __
Device Name: Evolution® Colonic Stent System
Indications for Use:
This device is used for palliative treatment of colonic obstruction or colonic strictures caused by malignant neoplasms, and to relieve large bowel obstruction prior to colectomy in patients with malignant strictures.
Prescription Use V (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use _ (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Dorat M. Why
(Division Sign-Off)
Division of Reproductive, Gastro-Renal, and
Urological Devices
510(k) Number K113510
Page 1 of 1